MEASUREMENT OF CIRCULATING MUTATION BURDEN

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Observational

Phase

Not applicable / not listed

Age range

30 years - 50 years

Sex eligible

Female

Healthy volunteers

Accepted

Participants

30 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

Cancer-free women with a hereditary predisposition to breast and/or ovarian cancer

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Female participant
• Participant undergoing oncogenetic follow-up at the Centre François Baclesse
• Participant belonging to a pair of related biological siblings
• Within the sibling pair, one participant is a carrier of a hereditary predisposition linked to a BRCA1/2 mutation (case), and the other participant is not a carrier (control).
• Participant between 30 and 50 years of age
• Participant affiliated to a social security scheme
• Participant having given her consent to participate by signing an informed consent form prior to any specific study-related procedure.

Exclusion Criteria:

• Male gender
• Current cancer or a history of cancer
• Current smoker or someone who quit smoking less than 10 years ago with a cumulative exposure of \> 10 packs/year)
• Presence of another hereditary predisposition to cancer
• History of risk-reduction surgery (adnexectomy, fimbriectomy, mastectomy)
• Chronic immunomodulatory treatment
• Patients who are incarcerated, under legal guardianship, subject to a legal protective measure, or unable to give informed consent
• Patients unable to participate in the study for geographic, social, or psychopathological reasons

Study population

Participant is a carrier of a hereditary predisposition linked to a BRCA1/2 mutation (case), and the other participant (sister) is not a carrier (control).

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Not reported

Masking

Not reported

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

Centre Francois Baclesse

Study start

Jul 4, 2025 Actual

Primary completion

Jul 15, 2029 Estimated

Study completion

Dec 30, 2029 Estimated

First posted

Jan 27, 2025 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts